August 25th 2025
Leqembi for the treatment of Alzheimer disease has been launched in Austria on August 25, 2025, and will be launched in Germany on September 1, 2025—the first launches in the EU.
Aphasia Following Acquired Brain Injury
June 26th 2023Aphasia is an impairment of language that frequently occurs following neurological injury, particularly stroke. Understanding the various types of aphasia, treatment modalities, and the importance of family education and training can empower clinicians in directing treatment.
Read More
Neurocognitive and Neuropsychiatric Consequences of COVID-19
June 14th 2023Many individuals infected with COVID-19 continue to experience symptoms after recovering from the initial viral infection. Persistent symptoms include neurocognitive and neuropsychiatric symptoms that can interfere with meaningful daily activities and roles. Given the symptom overlap, best practices and evidenced-based techniques for the treatment of concussion/mTBI can inform treatment approaches to manage symptoms and reduce the negative impact of long COVID.
Read More
The Border Zone Between bvFTD and Primary Psychiatric Disorders
April 24th 2023In this CME, learn more about frontotemporal lobar degeneration and the several overlapping syndromes that it encompasses, as well as how to distinguish behavioral variant frontotemporal lobar degeneration from other psychiatric disorders.
Read More